Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Previous studies demonstrated that imatinib mesylate (IM) induces autophagy in chronic
myeloid leukemia (CML) and that this process is critical to cell survival upon therapy …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …

Chronic myeloid leukemia (CML) stem cell survival is not dependent on BCR-ABL protein
kinase and treatment with ABL tyrosine kinase inhibitors cures only a minority of CML …

The transcription factor signal transducers and activators of transcription 5 (STAT5) has an
important and unique role in Breakpoint Cluster Region-Abelson 1 (BCR-ABL1)–driven …

Targeting the fusion oncoprotein BCR-ABL with tyrosine kinase inhibitors has significantly
affected chronic myeloid leukemia (CML) treatment, transforming the life expectancy of …

The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …

Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …

TOX is a nuclear factor essential for the development of CD4+ T cells in the thymus. It is
normally expressed in low amounts in mature CD4+ T cells of the skin and the peripheral …